The European Pharmacopoeia (Ph. Eur.) Monograph 0478 is the definitive general monograph governing the quality, production, and testing standards for Tablets within the European Union. Understanding this monograph is essential for pharmaceutical manufacturers to ensure batch-to-batch consistency and regulatory compliance. Core Requirements of Monograph 0478
The Compliance Gap: A major European study involving 22 countries found that many tablets with "breakage notches" actually failed these strict Ph. Eur. requirements, highlighting the ongoing challenge for manufacturers to perfect tablet design. 2. Dissolution: The "Clockwork" Release european pharmacopoeia ph eur monograph tablets 0478 better
If a tablet has a break-mark to allow for fractional dosing, the effectiveness of that break-mark must be validated: The European Pharmacopoeia (Ph
) states otherwise. It defines tablets as solid preparations each containing a single dose of one or more active substances, usually obtained by compressing uniform volumes of particles. Key Quality Requirements The name of the active substance(s) and quantity per tablet
Why it’s better: The monograph includes a "Tablets that are hygroscopic" clause, requiring testing at controlled humidity (e.g., 50-60% RH) – a nuance many other standards ignore. This prevents tablets that crumble in a bottle after three months in a humid climate.
Tablets must generally comply with the following standardized tests:
The Ph. Eur. monograph for tablets (0478) has significant implications for pharmaceutical manufacturers: